Close Menu

NEW YORK (GenomeWeb) – Food safety test developer Roka Bioscience announced today that it has signed an agreement to privately sell roughly 22,500 shares of preferred stock for $22.5 million.

According to the company, each share of the Series A preferred stock is convertible into approximately 1,428 shares of common stock, which is equivalent to a purchase price of $.70 per common share. For each preferred share, Roka said, purchasers will receive a five-year warrant to buy about 1,428 shares of common stock at $.70 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.